EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma

Arianna Giacomini, Sara Taranto, Giorgia Gazzaroli, Jessica Faletti, Davide Capoferri, Raffaella Marcheselli, Margherita Sciumè, Marco Presta, Antonio Sacco, Aldo M Roccaro

Journal of Experimental & Clinical Cancer Research · 2024

DOI: 10.1186/s13046-024-03217-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Experimental & Clinical Cancer Research, 2024. Verfasst von Arianna Giacomini und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy. arianna.giacomini@unibs.it. Hauptthemen laut MEDLINE: Multiple Myeloma, Receptors, Fibroblast Growth Factor, Fibroblast Growth Factors, Proto-Oncogene Proteins c-myc. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Among blood cancers, multiple myeloma (MM) represents the second most common neoplasm and is characterized by the accumulation and proliferation of monoclonal plasma cells within the bone marrow. Despite the last few decades being characterized by the development of different therapeutic strategies against MM, at present such disease is still considered incurable. Although MM is highly heterogeneous in terms of genetic and molecular subtypes, about 67% of MM cases are associated with abnormal activity of the transcription factor c-Myc, which has so far revealed a protein extremely difficult to target. We have recently demonstrated that activation of fibroblast growth factor (FGF) signaling protects MM cells from oxidative stress-induced apoptosis by stabilizing the oncoprotein c-Myc. Accordingly, secretion of FGF ligands and autocrine activation of FGF receptors (FGFR) is observed in MM cells and FGFR3 genomic alterations represent some 15–20% MM cases and are associated with poor outcome. Thus, FGF/FGFR blockade may represent a promising strategy to indirectly target c-Myc in MM. On this basis, the present review aims at providing an overview of recently explored connections between the FGF/FGFR system and c-Myc oncoprotein, sustaining the therapeutic potential of targeting the FGF/FGFR/c-Myc axis in MM by using inhibitors targeting FGF ligands or FGF receptors. Importantly, the provided findings may represent the rationale for using FDA approved FGFR TK inhibitors (i.e. Pemigatinib, Futibatinib, Erdafitinib) for the treatment of MM patients presenting with an aberrant activation of this axis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaReceptors, Fibroblast Growth FactorFibroblast Growth FactorsProto-Oncogene Proteins c-mycHumansSignal TransductionMolecular Targeted TherapyAnimals

Stichwörter der Autor:innen

C-MycFGF/FGFR systemMultiple myeloma

Substanzen

Receptors, Fibroblast Growth FactorFibroblast Growth FactorsProto-Oncogene Proteins c-myc

Autor:innen und Institutionen

  • Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy. arianna.giacomini@unibs.it.
  • Clinical Trial Center, Translational Research and Phase I Unit, ASST Spedali Civili Di Brescia, Brescia, Italy.
  • Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
  • Clinical Trial Center, Translational Research and Phase I Unit, ASST Spedali Civili Di Brescia, Brescia, Italy. aldomaria.roccaro@asst-spedalicivili.it.

Zitieren

APA

Giacomini, A., Taranto, S., Gazzaroli, G., Faletti, J., Capoferri, D., Marcheselli, R., Sciumè, M., Presta, M., Sacco, A., & Roccaro, A. M. (2024). The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-024-03217-2

Vancouver

Giacomini A, Taranto S, Gazzaroli G, Faletti J, Capoferri D, Marcheselli R, et al. The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma. Journal of Experimental & Clinical Cancer Research. 2024. doi:10.1186/s13046-024-03217-2

BibTeX
@article{Giacomini2024,
  author = {Giacomini, Arianna and Taranto, Sara and Gazzaroli, Giorgia and Faletti, Jessica and Capoferri, Davide and Marcheselli, Raffaella and Sciumè, Margherita and Presta, Marco and Sacco, Antonio and Roccaro, Aldo M},
  title = {The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma},
  journal = {Journal of Experimental & Clinical Cancer Research},
  year = {2024},
  doi = {10.1186/s13046-024-03217-2}
}
Kostenlos starten →